Bio-Techne Corporation announced it will showcase its market-leading portfolio to advance cancer research from target discovery to personalized medicine and cell therapy development at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas. Bio-Techne's spatial biology brands, Advanced Cell Diagnostics (ACD) and Lunaphore, are revolutionizing spatial biology research with their pioneering innovations that are advancing the development of tailored immunotherapies to improve patient outcomes. At booth #613, ACD will present its wide range of spatial multiomics products.

These products leverage the precise RNAscope technology and an advanced protease-free workflow for same-section RNA and protein detection assays. In combination, these capabilities empower drug discovery research, accelerate cell and gene therapy workflows, enable the characterization of key soluble factors and the immune landscape, and support the development of improved diagnostic tools for an accelerated path from translational research to clinical applications. At booth #701, Lunaphore will showcase its fully-automated, end-to-end COMET suite, designed to provide innovative solutions in spatial biology for the translational research community.

The complete portfolio will be showcased through product demonstrations. Furthermore, attendees can test the HORIZON image analysis software, tailored for COMET hyperplex images, offering new features for intuitive multiomics data and neighborhood analysis. Several scientists from the company and its partners will present posters at the conference highlighting how the capabilities of Bio-Techne's solutions enable key research and clinical applications.